Biorestorative Therapies (NASDAQ:BRTX) Announces Quarterly Earnings Results

Biorestorative Therapies (NASDAQ:BRTX) posted its earnings results on Thursday. The company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37), Zacks reports. Biorestorative Therapies had a negative net margin of 3,308.09% and a negative return on equity of 231.08%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.15 million.

Biorestorative Therapies Price Performance

Shares of BRTX stock traded down $0.01 during mid-day trading on Friday, hitting $0.29. The company had a trading volume of 875,205 shares, compared to its average volume of 9,431,650. The stock’s 50 day moving average price is $0.56 and its 200-day moving average price is $1.07. Biorestorative Therapies has a 52-week low of $0.19 and a 52-week high of $2.05. The company has a market capitalization of $2.61 million, a P/E ratio of -0.20 and a beta of 0.47.

Hedge Funds Weigh In On Biorestorative Therapies

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BRTX. Citadel Advisors LLC bought a new stake in Biorestorative Therapies during the 3rd quarter valued at $152,000. DRW Securities LLC bought a new stake in shares of Biorestorative Therapies in the fourth quarter valued at about $55,000. Finally, Virtu Financial LLC lifted its stake in Biorestorative Therapies by 102.4% in the third quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares during the period. 69.38% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.